Search

Displaying results 3711 - 3720 of 4233 in total
  1. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

  2. Drug

    INCB13739

    go.drugbank.com/drugs/DB05064
    Investigational

    INCB13739 is developed as a new treatment for type 2 diabetes.

  3. Drug

    Matuzumab

    go.drugbank.com/drugs/DB05101
    Investigational

    Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment.

  4. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    As a result, Sanofi stopped the development of the drug.

  5. Drug

    Oxalic Acid

    go.drugbank.com/drugs/DB03902
    Experimental

    It is used as an analytical reagent and general reducing agent. [PubChem]

  6. Drug

    Virginiamycin S1

    go.drugbank.com/drugs/DB04805
    Experimental

    It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.

  7. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine

  8. Drug

    AEM-28-14

    go.drugbank.com/drugs/DB17643
    Experimental

    [L45909] It is being investigated for lipid disorders such as homozygous familial hypercholesterolemia.[L45914]

  9. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    Echinacoside is a phenylethanoid glycoside isolated from Echinacea angustifolia in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis, acute colitis, wound treatment, and h...

  10. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    Pibrentasvir is available as an oral combination therapy with [DB13879] under the brand name Mavyret. … As of June 2025, the FDA approved an expanded indication for Mavyret, making it the first and only direct-acting antiviral therapy approved for the treatment of both acute and chronic HCV in patients aged